bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
0.2470
+0.0103 (4.35%)
At close: Sep 3, 2025, 4:00 PM
0.2450
-0.0020 (-0.81%)
After-hours: Sep 3, 2025, 6:39 PM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.27M in the quarter ending June 30, 2025, a decrease of -47.05%. This brings the company's revenue in the last twelve months to $7.68M, up 4.99% year-over-year. In the year 2024, bioAffinity Technologies had annual revenue of $9.36M with 269.68% growth.
Revenue (ttm)
$7.68M
Revenue Growth
+4.99%
P/S Ratio
0.54
Revenue / Employee
$134,755
Employees
57
Market Cap
6.96M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
Dec 31, 2022 | 4.80K | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BIAF News
- 16 days ago - bioAffinity Technologies Appoints New Members to Board of Directors - Business Wire
- 20 days ago - bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - Business Wire
- 20 days ago - bioAffinity Technologies Reports Second Quarter 2025 Results - Business Wire
- 21 days ago - bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - Business Wire
- 21 days ago - bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales - Business Wire
- 5 weeks ago - Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results - Business Wire
- 6 weeks ago - Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic - Business Wire
- 7 weeks ago - bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic - Business Wire